Evolocumab

Evolocumab is a fully human monoclonal antibody, a large protein produced by biotechnology to bind a specific target ^[1][2]. It belongs to the PCSK9 inhibitor class of cholesterol-lowering drugs, named for the protein they block ^[1]. Unlike statins, which are small molecules taken as pills, evolocumab is a biologic administered by subcutaneous injection ^[1][2]. It works alongside, rather than in place of, other lipid-lowering treatments and can drive LDL cholesterol to very low levels ^[1][2].

The drug is used to treat hypercholesterolemia, particularly in people who cannot reach their cholesterol goals on statins alone or who cannot tolerate statins, and in those with familial hypercholesterolemia, an inherited condition of very high LDL cholesterol ^[1][3]. In a trial in patients with heterozygous familial hypercholesterolemia, evolocumab reduced LDL cholesterol by roughly 60% on top of existing therapy and was well tolerated ^[3]. It is also approved to lower the risk of heart attack, stroke, and coronary procedures in people with established cardiovascular disease ^[1][2].

The pivotal evidence for its cardiovascular benefit came from the large FOURIER trial, which enrolled more than 27,000 patients with atherosclerotic disease already taking statins ^[2]. Adding evolocumab lowered LDL cholesterol to a median of about 30 mg per deciliter and significantly reduced the combined risk of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, and coronary revascularization, with the main side-effect difference being more frequent injection-site reactions ^[2]. A prespecified analysis found the benefit was consistent in patients with and without diabetes and that the drug did not raise the risk of developing diabetes or worsen blood sugar control ^[4].

Evolocumab was developed by the biotechnology company Amgen and approved in the United States, Europe, and Canada in 2015, marketed as Repatha ^[1]. It is a prescription-only medicine supplied as a prefilled pen or syringe for injection under the skin, typically every two weeks or once a month ^[1]. It is generally well tolerated; the most common adverse effects are reactions at the injection site, such as redness or pain, along with cold-like symptoms and muscle aches ^[1][3]. Its high cost was initially a barrier to access, and prices were later reduced ^[1].

Evolocumab is a prescription biologic given by injection and is generally very well tolerated. The most common effects are injection site reactions, cold like symptoms, muscle aches and occasional flu like feelings, with rare allergic reactions. In the large outcomes trial it did not raise rates of new diabetes or meaningful memory problems, and driving LDL to very low levels appeared safe. Because it is an antibody rather than a small molecule, it does not carry the liver or muscle interaction concerns of some oral drugs. People allergic to the product should not use it, and it should be stored cold until shortly before injecting.

Evolocumab is a fully human monoclonal antibody developed by Amgen to target PCSK9, a protein whose role in cholesterol metabolism had been uncovered only about a decade before the drug's approval. The story began in the early 2000s, when geneticists studying families with unusually high and unusually low cholesterol traced the differences to mutations in the PCSK9 gene, revealing that the protein controls how many LDL receptors the liver keeps on its surface.

This discovery pointed directly to a therapeutic strategy: block PCSK9, spare the receptors, and let the liver clear more LDL cholesterol from the blood. Evolocumab, an antibody that binds PCSK9 and prevents it from degrading the receptors, received United States Food and Drug Administration approval in 2015 and was marketed as Repatha. Its cardiovascular benefit was confirmed by the large FOURIER outcomes trial, published in 2017, which showed that adding evolocumab to statin therapy reduced the risk of major cardiovascular events.

Evolocumab is widely regarded as one of the most powerful cholesterol-lowering agents available, capable of reducing LDL cholesterol by roughly 60 percent on top of a statin, often driving levels lower than was previously thought achievable or even desirable. Its reputation is anchored in the FOURIER trial, which enrolled more than 27,000 patients and demonstrated that pushing LDL down to very low levels translated into fewer heart attacks, strokes, and revascularizations.

It has proven especially valuable for people with familial hypercholesterolemia or established cardiovascular disease who cannot reach their targets with statins alone, and its safety profile in trials was reassuring, with injection-site reactions being the main distinguishing complaint. The candid caveats are that it is given by subcutaneous injection every two weeks or monthly and that, as a biologic, it is considerably more expensive than generic statins. For patients who need aggressive LDL reduction, however, it represents a genuinely potent and evidence-backed advance.